*Table 1*. CRN Shared Database Core Dataset Survey Results.

|  |  |
| --- | --- |
| **>70% respondents viewed as critical (n=27)** | **50-70% respondents viewed as critical (n=17)** |
|  | * Demographics
 |  | * Alcohol history
 |
|  | * Smoking history
 |  | * Chronic back pain details
 |
|  | * Family history (of psoriasis, PsA, AS, SpA, IBD)
 |  | * PsA subtype (poly, oligo, mutilans, axial predominant, DIP predominant)
 |
|  | * Extra articular features (IBD, uveitis)
 |   |  |
|  | * Musculoskeletal history (current and previous)
 |   |  |
|  | * Skin history
 |   |  |
|  | * Date of diagnosis (year) psoriasis and PsA
 |   |  |
|  | * CASPAR criteria
 |   |  |
|  | **Co-morbidities** |  | **Co-morbidities** |
|  | * Obesity
 |  | * Hypertension
 |
|   |  | * Diabetes
 |
|   |  | * Hyperlipidaemia
 |
|   |  | * Previous cardiovascular event
 |
|   |  | * Depression
 |
|  | **Medication** |  | **Medication** |
|  | * Previous medicines
 |   |
|  | * Current medicines
 |   |
|  | **Psoriasis\*** |  | **Psoriasis** |
|   |  | * BSA
 |
|  | **Nails\*** |  | **Nails** |
|   |  | * Nail pitting
 |
|   |  | * Onycholysis
 |
|  | **Enthesitis\*** |  | **Enthesitis** |
|   |  | * LEI
 |
|  | **Dactylitis** |  | **Dactylitis** |
|  | * Tender dactylitis count
 |   |
|  | **Joint count** |  | **Joint count** |
|  | * 68 Tender joint count
 |   |
|  | * 66 Swollen joint count
 |   |
|  | **Physicians Global Assessment** |  | **Physicians Global Assessment** |
|  | * Global disease activity
 |  | * Arthritis activity
 |
|   |  | * Skin disease
 |
|  | **Axial disease** |  | **Axial disease** |
|  | * BASDAI
 |   |
|  | **Composite measures** |  | **Composite measures** |
|  | * MDA
 |   |
|  | **PROMs** |  | **PROMs** |
|  | * BASDAI (if IBP symptoms)
 |  | * Patient VAS: global disease
 |
|  | * DLQI
 |  | * Patient VAS: global pain
 |
|  | * mHAQ
 |   | * mHAQ
 |
|  | * Patient global assessment of joint disease
 |   |  |
|  | * Patient global assessment of skin disease
 |   |  |
|  | * PsAID12
 |   |  |
|  | **LABs** |  | **LABs** |
|  | * ACPA (level and unit)
 |  | * ESR
 |
|  | * Rheumatoid factor (level and unit)
 |   |  |
|  | * HLA-B27
 |   |  |
|  | * CRP (level and unit)
 |  |  |

CRN: Collaborative Research Network; n: number; PsA: psoriatic arthritis; AS: ankylosing spondylitis; SpA: spondyloarthritis; IBD: inflammatory bowel disease; DIP: distal interphalangeal; CASPAR: ClASsification for PsA; BSA: body surface area; LEI: Leeds Enthesitis Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; MDA: minimal disease activity; PROMs: Patient-Reported Outcome Measures; IBP: inflammatory back pain; VAS: visual analog scale; DLQI: Dermatology Life Quality Index; mHAQ: modified Health Assessment Questionnaire; PsAID12: Psoriatic Arthritis Impact of Disease questionnaire; ACPA: anti-citrullinated protein antibodies; ESR: erythrocyte sedimentation rate; HLA-B27: human leukocyte antigen-B27; CRP: C-reactive protein.

\* >70% respondents agreed that domain items should be included, but there was no consensus on which instrument items to include.